Earnings call transcript: Madrigal beats Q3 2026 estimates, posts first profit

Madrigal reported Q3 2026 EPS of $1.83 versus analysts’ forecast for a loss of $0.83, revenue of $431.3 million versus $405.27 million expected, and its first profitable quarter, with net income of $55.4 million. Revenue rose 50% year over year, year-to-date net sales reached $1.1 billion, and active REZDIFFRA patients nearly doubled to 55,850; management expects continued growth but cautioned that profitability may vary quarter to quarter. Shares rose 0.64% in premarket trading to $433.90.

Analysis

The key underwriting question is whether patient growth converts into durable net revenue and cash generation—not whether one quarter can clear break-even. Gross-to-net already absorbs a substantial share of demand, Medicare contracting adds a 2027 sensitivity, and commercial build-out plus the new F4C trial can keep earnings lumpy. Thus, the first profit is evidence of operating leverage, not yet proof of a stable margin floor. Roche Holding Ltd (ROP) is a secondary beneficiary through royalties; stronger MDGL sales do not flow dollar-for-dollar to MDGL shareholders.

Near term, a large estimate beat with a muted share response argues against chasing the print; it may reflect elevated expectations, but does not establish that the growth thesis is priced in. Over 1–3 months, monitor quarterly patient additions, net sales relative to patient growth, and any change to the 2026 gross-to-net outlook. The bigger 6–18 month risk is a 2027 access-versus-growth trade-off: Part D concessions or higher selling costs could slow margin expansion even as prescriptions rise. Late-2027 F4C outcomes offer material upside optionality, but event-driven timing can slip and the additional CSPH study raises investment needs before it yields evidence.

Contrarian point: GLP-1 adoption may expand diagnosis and treatment pathways rather than simply displace REZDIFFRA today; that supports the category, but could also raise the future efficacy bar and strengthen combination competitors. Management’s very large market claims are hypotheses, not a basis for extrapolating the current run rate indefinitely.

Key Decisions for Investors

• Do not chase MDGL on the earnings beat. Consider a staged long only on consolidation, sized for biotech/trial risk; reassess against valuation and updated estimates, which are not supplied here.
• Track net sales versus active patients and gross-to-net at the next report. A slowdown in sales per patient alongside rising concessions or SG&A would weaken the margin-leverage thesis; stable/improving conversion would support it.
• Treat the late-2027 F4C readout as a catalyst, not as current earnings value. Revisit exposure if timing moves beyond late 2027, event accrual disappoints, or FDA alignment on the CSPH protocol is unfavorable.
• ROP offers indirect royalty exposure to REZDIFFRA growth, but the supplied data do not quantify the royalty economics; verify reported royalty contribution before expressing a standalone trade.